ID   MIP/CPT
AC   CVCL_HE63
DR   cancercelllines; CVCL_HE63
DR   Wikidata; Q54905754
RX   PubMed=15902309;
CC   Selected for resistance to: ChEBI; CHEBI_80630; Irinotecan (Camptothecin-11; CPT-11).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_H689 ! MIP-101
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 19-12-24; Version: 9
//
RX   PubMed=15902309; DOI=10.1172/JCI23002; PMCID=PMC1090471;
RA   Tai I.T., Dai M., Owen D.A., Chen L.-B.;
RT   "Genome-wide expression analysis of therapy-resistant tumors reveals
RT   SPARC as a novel target for cancer therapy.";
RL   J. Clin. Invest. 115:1492-1502(2005).
//